FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148470027> ?p ?o ?g. }

• W2148470027 endingPage "61" @default.
• W2148470027 startingPage "56" @default.
• W2148470027 abstract "Melphalan 200 mg/m2 is the standard conditioning regimen for patients with multiple myeloma (MM) with normal renal function (NRF) undergoing autologous stem cell transplant (ASCT). In an effort to escalate the dose of melphalan and to improve the efficacy, we designed a dose-escalation study of melphalan in conjunction with palifermin in patients with NRF, with the hope that a higher dose of melphalan can be administered with an acceptable degree of oral mucositis (OM). We enrolled 19 patients (18 evaluable) with NRF. Dose-escalation of melphalan administered on day −2 began at 200 mg/m2 with palifermin administered at a fixed dose of 60 mcg/kg/day. Palifermin was given as an i.v. bolus on day −5, −4, and −3, and then on day +1, +2, and +3. Subsequent dose escalations of melphalan were done at 20 mg/m2 increments up to a maximum dose of 280 mg/m2. Of 18 evaluable patients, there were no treatment-related deaths by day 100. The median age was 48.5 years (range, 33-65 years). The most common adverse events related to palifermin included rash (18 events, no ≥grade 3 events), elevation of amylase (10 events, 4 were grade 3 but asymptomatic), and lipase (5 events, 2 were grade 3 but asymptomatic), edema (11 events, no ≥grade 3). The overall incidence of OM grade 3 was 44% (8/18) with a median duration of severe mucositis of 5 days (range, 3-6 days). Eleven patients (61%) required opioid analgesics. None of the patients received total parenteral nutrition (TPN)/nasogastric feeding. Two of 6 patients who were given melphalan 280 mg/m2 did not develop OM. Cardiac dose-limiting toxicity (DLT) in the form of atrial fibrillation did occur in 1 of 6 patients treated with melphalan 280 mg/m2. Palifermin has permitted safe dose escalation of melphalan up to 280 mg/m2, thus reaching the cumulative dosage of melphalan administered in tandem ASCT. This higher dose of melphalan has the potential to improve the efficacy and, hopefully, outcomes of patients with MM with a single ASCT. A phase 2 trial is necessary to better delineate the antimyeloma efficacy of this regimen." @default.
• W2148470027 created "2016-06-24" @default.
• W2148470027 creator A5005086749 @default.
• W2148470027 creator A5016774003 @default.
• W2148470027 creator A5028497782 @default.
• W2148470027 creator A5034791164 @default.
• W2148470027 creator A5037082058 @default.
• W2148470027 creator A5042677328 @default.
• W2148470027 creator A5046786751 @default.
• W2148470027 creator A5051092535 @default.
• W2148470027 creator A5055027283 @default.
• W2148470027 creator A5076385097 @default.
• W2148470027 creator A5086510250 @default.
• W2148470027 creator A5086538924 @default.
• W2148470027 creator A5091089490 @default.
• W2148470027 date "2013-01-01" @default.
• W2148470027 modified "2023-10-03" @default.
• W2148470027 title "A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function" @default.
• W2148470027 cites W1931964440 @default.
• W2148470027 cites W1969056907 @default.
• W2148470027 cites W1985482871 @default.
• W2148470027 cites W2002829541 @default.
• W2148470027 cites W2003111859 @default.
• W2148470027 cites W2010717111 @default.
• W2148470027 cites W2026295989 @default.
• W2148470027 cites W2059564700 @default.
• W2148470027 cites W2071606914 @default.
• W2148470027 cites W2073292917 @default.
• W2148470027 cites W2082134267 @default.
• W2148470027 cites W2088553059 @default.
• W2148470027 cites W2089107230 @default.
• W2148470027 cites W2097067451 @default.
• W2148470027 cites W2102591890 @default.
• W2148470027 cites W2107057207 @default.
• W2148470027 cites W2118063672 @default.
• W2148470027 cites W2120370912 @default.
• W2148470027 cites W2127143739 @default.
• W2148470027 cites W2152485160 @default.
• W2148470027 cites W2160115655 @default.
• W2148470027 cites W2161109822 @default.
• W2148470027 cites W2163320846 @default.
• W2148470027 cites W2589007063 @default.
• W2148470027 cites W3145716452 @default.
• W2148470027 cites W4211135634 @default.
• W2148470027 cites W4237181574 @default.
• W2148470027 cites W4317527937 @default.
• W2148470027 cites W4378951223 @default.
• W2148470027 doi "https://doi.org/10.1016/j.bbmt.2012.08.003" @default.
• W2148470027 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3786738" @default.
• W2148470027 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22892551" @default.
• W2148470027 hasPublicationYear "2013" @default.
• W2148470027 type Work @default.
• W2148470027 sameAs 2148470027 @default.
• W2148470027 citedByCount "18" @default.
• W2148470027 countsByYear W21484700272013 @default.
• W2148470027 countsByYear W21484700272014 @default.
• W2148470027 countsByYear W21484700272015 @default.
• W2148470027 countsByYear W21484700272016 @default.
• W2148470027 countsByYear W21484700272017 @default.
• W2148470027 countsByYear W21484700272018 @default.
• W2148470027 countsByYear W21484700272019 @default.
• W2148470027 countsByYear W21484700272020 @default.
• W2148470027 countsByYear W21484700272021 @default.
• W2148470027 countsByYear W21484700272022 @default.
• W2148470027 countsByYear W21484700272023 @default.
• W2148470027 crossrefType "journal-article" @default.
• W2148470027 hasAuthorship W2148470027A5005086749 @default.
• W2148470027 hasAuthorship W2148470027A5016774003 @default.
• W2148470027 hasAuthorship W2148470027A5028497782 @default.
• W2148470027 hasAuthorship W2148470027A5034791164 @default.
• W2148470027 hasAuthorship W2148470027A5037082058 @default.
• W2148470027 hasAuthorship W2148470027A5042677328 @default.
• W2148470027 hasAuthorship W2148470027A5046786751 @default.
• W2148470027 hasAuthorship W2148470027A5051092535 @default.
• W2148470027 hasAuthorship W2148470027A5055027283 @default.
• W2148470027 hasAuthorship W2148470027A5076385097 @default.
• W2148470027 hasAuthorship W2148470027A5086510250 @default.
• W2148470027 hasAuthorship W2148470027A5086538924 @default.
• W2148470027 hasAuthorship W2148470027A5091089490 @default.
• W2148470027 hasBestOaLocation W21484700271 @default.
• W2148470027 hasConcept C126322002 @default.
• W2148470027 hasConcept C141071460 @default.
• W2148470027 hasConcept C197934379 @default.
• W2148470027 hasConcept C2776364478 @default.
• W2148470027 hasConcept C2776694085 @default.
• W2148470027 hasConcept C2778496288 @default.
• W2148470027 hasConcept C2778570526 @default.
• W2148470027 hasConcept C2778684742 @default.
• W2148470027 hasConcept C2781413609 @default.
• W2148470027 hasConcept C2911091166 @default.
• W2148470027 hasConcept C71924100 @default.
• W2148470027 hasConcept C90924648 @default.
• W2148470027 hasConceptScore W2148470027C126322002 @default.
• W2148470027 hasConceptScore W2148470027C141071460 @default.
• W2148470027 hasConceptScore W2148470027C197934379 @default.
• W2148470027 hasConceptScore W2148470027C2776364478 @default.
• W2148470027 hasConceptScore W2148470027C2776694085 @default.
• W2148470027 hasConceptScore W2148470027C2778496288 @default.

• next